IRE-1α inhibitors
US8614253B2 · kind B2 · utility
7Cited by
122References
56Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 8, 2010 |
| Grant date | Dec 24, 2013 |
| Priority date | — |
| Expiry date | Jun 11, 2031 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.